A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
The purpose of the study is to evaluate the safety and tolerability of BNA035 in order to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to evaluate the preliminary efficacy for each combination regimen.
100 Clinical Results associated with Binacea Pharma, Inc.
0 Patents (Medical) associated with Binacea Pharma, Inc.
100 Deals associated with Binacea Pharma, Inc.
100 Translational Medicine associated with Binacea Pharma, Inc.